RVI has granted the underwriter a 30-day option to purchase up to an additional 1,892,341 common shares of beneficial ...

Copyright © 2026 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service ...

IMPERIAL PETROLEUM INC. (NASDAQ: IMPP; the “Company”), a ship-owning company providing petroleum products, crude oil and dry bulk seaborne transportation services, announced today its unaudited ...

All Four Post-Quantum Security Products on Track for Common Criteria, FIPS 140-3, and TCG Certifications Through Q4 2026 SEALSQ Corp (Nasdaq: LAES), ("SEALSQ" or "Company"), a leading provider of post ...

At the center of those concerns is the Strait of Hormuz, the narrow waterway through which roughly one-fifth of the world’s oil supply passes. While Iranian officials have denied initiating a blockade ...

The Special Meeting is scheduled to be held at 10:00 a.m., Pacific Time, on March 13, 2026, at the Company’s principal executive offices. Subject to stockholder approval of the Business Combination ...

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric ...

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the second quarter (twelve weeks) and the first 24 weeks of fiscal 2026, ended ...

(NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”), a leader in renewable fuels and chemicals as well as carbon management, today announced financial results for the fourth quarter and full ...

Q4 total sales grew 11%, and comparable store sales increased 4% Q4 net income was $310 million, and diluted EPS was $4.84 FY25 total sales grew ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...